Cutaneous and genital HPV-Associated lesions in HIV-infected patients

Clinics in Dermatology

Volumn 15, Issue 3, 1997, Pages 439-447

  Palefsky, Joel M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAC USC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANUS CARCINOMA; EPIDERMODYSPLASIA VERRUCIFORMIS; GENITAL TRACT INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; SCREENING; SEXUALLY TRANSMITTED DISEASE; SKIN INFECTION; UTERINE CERVICITIS; UTERINE CERVIX CARCINOMA; VIRUS TRANSMISSION; VULVOVAGINITIS; WART VIRUS;

EID: 0030844533     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(96)00155-1     Document Type: Article

References (75)

1. Palefsky JM, Holly EA. Molecular virology and epidemiology of human papillomavirus and cervical cancer. Cancer Epidemiol Biomarkers Prev 1995;4:415-48.
2. MacDougall DS. Ritonavir: First to prolong survival. J Int Assoc Phys AIDS Care 1996;2:38-44.
3. Laga M, Alary M, Nzila N, et al. Condom promotion, sexually transmitted diseases treatment, and declining incidence of HIV-1 infection in female Zairian sex workers. Lancet 1994;344:246-8.
4. Laga M, Manoka A, Kivuvu M, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993;7:95-102.
5. Smith-McCune KK, Weidner N. Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res 1994;54:800-4.
6. Bauer HM, Ting Y, Greer CE, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method [see comments]. JAMA 1991;265:472-7.
7. Ley C, Bauer HM, Reingold A, et al. Determinants of genital human papillomavirus infection in young women [see comments]. J Natl Cancer Inst 1991;83:997-1003.
8. Schiffman MH. Latest HPV findings: some clinical implications. Contemporary Obstet Gynecol 1993;38:27-40.
9. Schiffman MH. Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 1992;84:394-8.
10. Penn I. Cancer in the immunosuppressed organ recipient. Transplant Proc 1991;23:1771-2.
11. Ogunbiyi OA, Scholefield JH, Raftery AT, et al. Prevalence of anal human papillomavirus infection and intraepithelial neoplasia in renal allograft recipients. Br J Surg 1994;81:365-7.
12. Williams AB, Darragh TM, Vranizan K, et al. Anal and cervical human papillomavirus infection and risk of anal and cervical epithelial abnormalities in human immunodeficiency virus-infected women. Obstet Gynecol. 1994; 83:205-11.
13. Vernon SD, Reeves WC, Clancy KA, et al. A longitudinal study of human papillomavirus DNA detection in human immunodeficiency virus type 1-seropositive and -sero-negative women. J Infect Dis 1994;169:1108-12.
14. Sun XW, Ellerbrock TV, Lungu O, et al. Human papillomavirus infection in human immunodeficiency virus-seropositive women. Obstet Gynecol 1995;85:680-6.
15. Gemignani M, Maiman M, Fruchter RG, et al. CD4 lymphocytes in women with invasive and preinvasive cervical neoplasia. Gynecol Oncol 1995;59:364-9.
16. Vermund SH, Melnick SL. Human papillomavirus infection. In: Minkoff HL, DeHovitz JA, Duerr A, editors. HIV Infection in Women. New York: Raven Press, 1995:189-227.
17. Sillman FH, Sedlis A. Anogenital papillomavirus infection and neoplasia in immunodeficient women. Obstet Gynecol Clin North Am 1987;14:537-558.
18. Feingold AR, Vermund SH, Burk RD, et al. Cervical cytologic abnormalities and papillomavirus in women infected with human immunodeficiency virus. J Acq Imm Def Synd 1990;3:896-903.
19. Maiman M, Fruchter RG, Serur E, et al. Human immunodeficiency virus infection and cervical neoplasia. Gynecol Oncol 1990;38:377-82.
20. Schrager LK, Friedland GH, Maude D, et al. Cervical and vaginal squamous cell abnormalities in women infected with human immunodeficiency virus. J Acq Imm Def Synd 1989;2:570-5.
21. Spinillo A, Tenti P, Zappatore R, et al. Prevalence, diagnosis and treatment of lower genital neoplasia in women with human immunodeficiency virus infection. Eur J Obstet Gynecol Reprod Biol 1992;43:235-41.
22. Laga M, Icenogle JP, Marsella R, et al. Genital papillomavirus infection and cervical dysplasia-opportunistic complications of HIV infection. Int J Cancer. 1992;50:45-8.
23. Wright T, Jr., Ellerbrock TV, Chiasson MA, et al. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study. Obstet Gynecol 1994;84:591-7.
24. Klein RS, Ho GY, Vermund SH, et al. Risk factors for squamous intraepithelial lesions on Pap smear in women at risk for human immunodeficiency virus infection. J Infect Dis 1994;170:1404-9.
25. Mandelblatt JS, Fahs M, Garibaldi K, et al. Association between HIV infection and cervical neoplasia: implications for clinical care of women at risk for both conditions. AIDS 1992;6:173-8.
26. Johnson JC, Burnett AF, Willet GD, et al. High frequency of latent and clinical human papillomavirus cervical infections in immunocompromised human immunodeficiency virus-infected women. Obstet Gynecol 1992;79: 321-7.
27. Fruchter RG, Maiman M, Sillman FH, et al. Characteristics of cervical intraepithelial neoplasia in women infected with the human immunodeficiency virus. Am J Obstet Gynecol 1994;171:531-7.
28. Korn AP, Landers DV. Gynecologic disease in women infected with human immunodeficiency virus type 1. J Acq Imm Def Synd Hum Retrovirol 1995;9:361-70.
29. Castro K, Ward J, Slutsker L, et al. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41:1-19.
30. Rabkin CS, Yellin F. Cancer incidence in a population with a high prevalence of infection with human immunodeficiency virus type 1. J Natl Cancer Inst 1994;86:1711-6.
31. Rellihan MA, Dooley DP, Burke TW, et al. Rapidly progressing cervical cancer in a patient with human immunodeficiency virus infection. Gynecol Oncol 1990;36:435-8.
32. Maiman M, Tarricone N, Vieira J, et al. Colposcopic evaluation of human immunodeficiency virus-seropositive women. Obstet Gynecol 1991;78:84-8.
33. Sexually transmitted diseases treatment guidelines. MMWR 1993;42 (No. RR-14):90-1.
34. Wright TC Jr, Moscarelli RD, Dole P, et al. Significance of mild cytologic atypia in women infected with human immunodeficiency virus. Obstet Gynecol 1996;87:515-9.
35. Maiman M, Fruchter RG, Serur E, et al. Recurrent cervical intraepithelial neoplasia in human immunodeficiency virus-seropositive women. Obstet Gynecol 1993;82:170-4.
36. Wright TC Jr, Koulos J, Schnoll F, et al. Cervical intraepithelial neoplasia in women infected with the human immunodeficiency virus: outcome after loop electrosurgical excision. Gynecol Oncol 1994;55:253-8.
37. Fruchter RG, Maiman M, Sedlis A, et al. Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet Gynecol 1996; 87:338-44.
38. Beckmann AM, Daling JR, Sherman KJ, et al. Human papillomavirus infection and anal cancer. Int J Cancer 1989; 43:1042-9.
39. Palefsky JM, Gonzales J, Greenblatt RM, et al. Anal intraepithelial neoplasia and anal papillomavirus infection among homosexual males with group IV HIV disease. JAMA 1990;263:2911-6.
40. Zaki SR, Judd R, Coffield LM, et al. Human papillomavirus infection and anal carcinoma. Retrospective analysis by in situ hybridization and the polymerase chain reaction. Am J Pathol 1992;140:1345-55.
41. Palefsky J. Anal cancer in HIV-positive individuals: an emerging problem. AIDS 1994:283-95.
42. Daling JR, Weiss NS, Hislop TG, et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 1987;317:973-7.
43. Melbye M, Cote TR, Kessler L, et al. High incidence of anal cancer among AIDS patients. The AIDS/Cancer Working Group. Lancet 1994;343:636-9.
44. Kiviat N, Rompalo A, Bowden R, et al. Anal human papillomavirus infection among human immunodeficiency virus-seropositive and -seronegative men. J Infect Dis 1990;162:358-61.
45. Critchlow CW, Holmes KK, Wood R, et al. Association of human immunodeficiency virus and anal human papillomavirus infection among homosexual men. Arch Int Med 1992;152:1673-6.
46. Palefsky JM, Shiboski S, Moss A. Risk factors for anal human papillomavirus infection and anal cytologic abnormalities in HIV-positive and HIV-negative homosexual men. J Acq Imm Def Synd 1994;7:599-606.
47. Breese PL, Judson FN, Penley KA, et al. Anal human papillomavirus infection among homosexual and bisexual men: prevalence of type-specific infection and association with human immunodeficiency virus. Sex Transm Dis 1995;22:7-14.
48. Melbye M, Smith E, Wohlfahrt Nielson J, et al. Use of human papillomavirus tests in prediction of anogenital abnormality. Int J Cancer (in press).
49. Mellors JW, Kingsley LA, Rinaldo C Jr, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-9.
50. Scholefield JH, Hickson WG, Smith JH, et al. Anal intraepithelial neoplasia: part of a multifocal disease process. Lancet 1992;340:1271-3.
51. Melbye M, Sprogel P. Aetiological parallel between anal cancer and cervical cancer. Lancet 1991;338:657-9.
52. Palefsky JM, Holly EA, Hogeboom CJ, et al. Anal cytology as a screening tool for anal squamous intraepithelial lesions. J Acq Imm Def Synd (in press).
53. LeBoit PE. Dermatopathologic findings in patients infected with HIV. Dermatol Clin 1992;10:59-71.
54. Lobo DV, Chu P, Grekin RC, et al. Nonmelanoma skin cancers and infection with the human immunodeficiency virus. Arch Dermatol 1992;128:623-7.
55. Holmberg SD, Buchbinder SP, Conley LJ, et al. The spectrum of medical conditions and symptoms before acquired immunodeficiency syndrome in homosexual and bisexual men infected with the human immunodeficiency virus. Am J Epidemiol 1995;141:395-404; discussion 405-396.
56. Lutzner MA, Blancet-Bardon C, Orth G. Clinical observations, virologic studies, and treatment trials in patients with epidermodysplasia verruciformis, a disease induced by specific papillomaviruses. J Invest Dermatol 1984;83: 18S-25S.
57. Androphy EJ, Dvortzky I, Lowy DR. X-linked inheritance of epidermodysplasia verruciformis: genetic and virologic studies of a kindred. Arch Dermatol 1985;121:864-8.
58. Jablonska S. Wart viruses: Human papillomaviruses. Sem Dermatol 1984;3:120-9.
59. Kanda R, Tanigaki T, Kitano Y, et al. Types of human papillomavirus isolated from Japanese patients with epidermodysplasia verruciformis. Br J Dermatol 1989;121: 463-9.
60. Obalek S, Favre M, Szymanczyk J, et al. Human papillomavirus (HPV) types specific of epidermodysplasia verruciformis detected in warts induced by HPV3 or HPV3-related types in immunosuppressed patients. J Invest Dermatol 1992;98:936-41.
61. Jabłońska S, Orth G. Epidermodysplasia verruciformis. Clin Dermatol 1985;3:83-96.
62. Salmon R, Thompson C, Rose B, et al. Epidermodysplasia verruciformis associated with multiple squamous cell carcinomas. Aust J Dermatol 1988;29:9-15.
63. Berger TG, Sawchuk WS, Leonardi C, et al. Epidermodysplasia verruciformis-associated papillomavirus infection complicating human immunodeficiency virus disease. Br J Dermatol 1991;124:79-83.
64. Rudlinger R, Bunney MH, Smith IW, et al. Detection of a human papilloma virus type 5 DNA in a renal allograft patient from Scotland. Dermatologica 1988;177:280-6.
65. Gross G, Ellinger K, Roussaki A, et al. Epidermodysplasia verruciformis in a patient with Hodgkin's disease: characterization of a new papillomavirus type and Interferon treatment. J Invest Dermatol 1988;91:43-8.
66. Tanagaki T, Kanda R, Sato K. Epidermodysplasia verruciformis in a patient with systemic lupus erythematosis. Arch Dermatol Res 1986;278:247-8.
67. Maurer TA, Vin Christian K, Kershmann RL, et al. Cutaneous squamous cell carcinoma in HIV-infected patients - a study of epidemiologic risk factors, human papillomavirus and p53 expression. Arch Dermatol (in press).
68. Shamanin V, zur Hausen H, Lavergne D, et al. Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients [see comments]. J Natl Cancer Inst 1996; 88:802-11.
69. Nuovo GJ, Forde A, MacConnell P, et al. In situ detection of PCR-amplified HIV-1 nucleic acids and tumor necrosis factor. Am J Pathol 1993;143:40-8.
70. Matsumoto T, Miike T, Nelson RP, et al. Elevated serum levels of IL-8 in patients with HIV infection. Clin Exp Immunol 1993;93:149-51.
71. Honda M, Kitamura K, Mizutani Y, et al. Quantitative analysis of serum IL-6 and its correlation with increased levels of serum IL-2R in HIV-induced diseases. J Immunol 1990;145:4059-64.
72. Hober D, Haque A, Wattre P, et al. Production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1) in patients with AIDS. Enhanced level of TNF-alpha is related to a higher cytotoxic activity. Clin Exp Immunol 1989;78:329-33.
73. Roux-Lombard P, Modoux C, Cruchaud A, et al. Purified blood monocytes from HFV 1-infected patients produce high levels of TNF alpha and IL-1. Clin Immunol Immunopathol 1989;50:374-84.
74. Steffen M, Reinecker HC, Petersen J, et al. Differences in cytokine secretion by intestinal mononuclear cells, peripheral blood monocytes and alveolar macrophages from HIV-infected patients. Clin Exp Immunol 1993;91:30-6.
75. Majewski S, Hunzelmann N, Nischt R, et al. TGF beta-1 and TNF alpha expression in the epidermis of patients with epidermodysplasia verruciformis. J Invest Dermatol 1991;97:862-7.